These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31361382)

  • 1. Safety and efficacy of emicizumab and other novel agents in newborns and infants.
    Pierce GF; Hart DP; Kaczmarek R;
    Haemophilia; 2019 Sep; 25(5):e334-e335. PubMed ID: 31361382
    [No Abstract]   [Full Text] [Related]  

  • 2. Initiation of emicizumab prophylaxis in an infant with haemophilia A and subdural haemorrhage.
    Bush KA; Lucas TL; Haley KM; Thornburg CD
    Haemophilia; 2020 Nov; 26(6):e353-e355. PubMed ID: 32892446
    [No Abstract]   [Full Text] [Related]  

  • 3. Emicizumab should be prescribed independent of immune tolerance induction.
    Le Quellec S; Negrier C
    Blood Adv; 2018 Oct; 2(20):2783-2786. PubMed ID: 30352952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies.
    Weyand AC; Flood VH; Shavit JA; Pipe SW
    Blood Adv; 2019 Sep; 3(18):2748-2750. PubMed ID: 31540901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of emicizumab on thrombin generation: A case report of breakthrough bleeding during emicizumab treatment.
    Valke LLFG; Beckers EAM; Blijlevens NMA; van Heerde WL; Schols SEM
    Haemophilia; 2020 Nov; 26(6):e327-e330. PubMed ID: 32596863
    [No Abstract]   [Full Text] [Related]  

  • 6. A boy with joint pain associated with emicizumab treatment: The importance of plasma level measurement.
    Hooimeijer HL; Lukens MV; Verhagen MV; Meijer K; Stein-Wit MA; Tamminga RYJ
    Haemophilia; 2020 May; 26(3):e138-e140. PubMed ID: 32297683
    [No Abstract]   [Full Text] [Related]  

  • 7. The factor VIII heavy chain improves emicizumab-tenase assembly to enhance the factor VIII-mimicking cofactor activity.
    Minami H; Nogami K; Soeda T; Kitazawa T; Hattori K; Shima M
    Thromb Res; 2018 Jun; 166():77-79. PubMed ID: 29684725
    [No Abstract]   [Full Text] [Related]  

  • 8. Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring.
    Biron-Andreani C; Diaz-Cau I; Ranc A; Navarro R; Leonardi C; Dischino M; Guy R; Theron A; Garcia-Gournay C; Santagostino E; Schved JF
    Br J Haematol; 2020 May; 189(3):e100-e103. PubMed ID: 32087028
    [No Abstract]   [Full Text] [Related]  

  • 9. Emicizumab-kxwh: First Global Approval.
    Scott LJ; Kim ES
    Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.
    Kitazawa T; Shima M
    Int J Hematol; 2020 Jan; 111(1):20-30. PubMed ID: 30350119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombin exhibits anticoagulant effects on the emicizumab-based engineered bispecific antibody (NXT007)-mediated blood coagulation.
    Nakajima Y; Ogiwara K; Inaba K; Kitazawa T; Nogami K
    Thromb Res; 2024 May; 237():14-17. PubMed ID: 38531118
    [No Abstract]   [Full Text] [Related]  

  • 13. Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance.
    Young G
    Blood Adv; 2018 Oct; 2(20):2780-2782. PubMed ID: 30352951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII.
    Gundabolu K; Goldsweig A; Bhatt VR; Koepsell SA; Harper JL
    Haemophilia; 2020 Jan; 26(1):e5-e8. PubMed ID: 31694063
    [No Abstract]   [Full Text] [Related]  

  • 15. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
    Batsuli G; Zimowski KL; Tickle K; Meeks SL; Sidonio RF
    Haemophilia; 2019 Sep; 25(5):789-796. PubMed ID: 31373431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort.
    Barg AA; Avishai E; Budnik I; Levy-Mendelovich S; Barazani TB; Kenet G; Livnat T
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27886. PubMed ID: 31348595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emicizumab (Hemlibra) for subcutaneous prophylaxis in hemophilia A.
    Med Lett Drugs Ther; 2019 May; 61(1572):77-79. PubMed ID: 31169801
    [No Abstract]   [Full Text] [Related]  

  • 18. Preface.
    Makowski GS
    Adv Clin Chem; 2019; 88():ix. PubMed ID: 30612609
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parent testimonial: A caregiver whose son with inhibitors has been receiving emicizumab.
    Page D
    Transfus Apher Sci; 2019 Oct; 58(5):563-564. PubMed ID: 31706912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.